首页> 外文期刊>International Journal of Cardiology >Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice
【24h】

Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice

机译:可溶性鸟苷酸环化酶刺激剂riociguat和磷酸二酯酶5抑制剂西地那非可减轻小鼠左心疾病引起的肺动脉高压

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Presence of pulmonary hypertension (PH) and right ventricular dysfunction worsens prognosis in patients with chronic heart failure (CHF). Preclinical and clinical studies suggest a role for the impaired nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway in both PH and CHF. Hence, we examined the effects of the NO-sGC-cGMP pathway modulation by the PDE5 inhibitor sildenafil or sGC stimulator riociguat on pulmonary hemodynamics and heart function in a murine model of secondary PH induced by transverse aortic constriction.
机译:背景:慢性心力衰竭(CHF)患者的肺动脉高压(PH)和右心室功能障碍的存在使预后恶化。临床前和临床研究表明,一氧化氮(NO)-可溶性鸟苷酸环化酶(sGC)-环鸟苷单磷酸(cGMP)信号通路受损在PH和CHF中均起作用。因此,我们检查了由PDE5抑制剂sildenafil或sGC刺激剂riociguat调节NO-sGC-cGMP途径对横向主动脉缩窄诱发的继发性PH的鼠模型中肺血流动力学和心脏功能的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号